Beta-hydroxybutyric acid compositions for oral delivery are substantially free of beta-hydroxybutyrate salts and are effective in rapidly raising blood ketone levels without causing acute acidosis or gastrointestinal (GI) distress when consumed in sufficiently dilute form and/or as a gel or suspension. By excluding beta-hydroxybutyrate salts (e.g., less than 1% by weight) containing alkali or alkaline earth metal ions, beta-hydroxybutyric acid solutions, gels, or suspensions can deliver exogenous ketone bodies without significantly altering electrolyte balance. Although aqueous beta-hydroxybutyric acid solutions are moderately acidic with a pH of about 3.5 to 4, when diluted with sufficient water, the water acts as a pseudo buffering agent that offsets otherwise harsh acidic effects when consumed orally. Gels and suspensions can also ameliorate acidic effects by partially encapsulating the beta-hydroxybutyric acid. Beta-hydroxybutyric acid can be enriched with the R- or the S-enantiomer, a racemic mixture, pure R-beta-hydroxybutyric acid, or pure S-beta-hydroxybutyric acid.

The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.

The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.

The present disclosure relates to, inter alia, a method of treating cancer in a human patient in need thereof, comprising administering a therapeutically effective amount of a substrate of AKR1B1, AKR1B10, or both to said patient, wherein said patient has, or is suspected to have, cancer cells with elevated levels of AKR1B1, AKR1B10, or both, wherein said substrate is not 2-deoxy-D-glucose.

The present invention relates to the use of a combination of a yeast of the species Saccharomyces cerevisiae, resveratrol and a curcuma extract, for use in the management of a subject who has endometriosis or is susceptible to endometriosis. The combination according to the invention may be used in the treatment or prevention of endometriotic lesions in a subject who has endometriosis or is susceptible to endometriosis, for example to slow the development or to reduce the endometriotic lesions. It may also be used in the treatment or prevention of one or more symptoms or disorders associated with endometriosis. The invention also relates to pharmaceutical or nutraceutical compositions and kits based on said combination.

The present invention relates to the use of a combination of a yeast of the species Saccharomyces cerevisiae, resveratrol and a curcuma extract, for use in the management of a subject who has endometriosis or is susceptible to endometriosis. The combination according to the invention may be used in the treatment or prevention of endometriotic lesions in a subject who has endometriosis or is susceptible to endometriosis, for example to slow the development or to reduce the endometriotic lesions. It may also be used in the treatment or prevention of one or more symptoms or disorders associated with endometriosis. The invention also relates to pharmaceutical or nutraceutical compositions and kits based on said combination.

The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.

The present invention relates to administration or application of a crosslink inducing agent to a subject following a stiffening procedure to the respiratory system. The present invention has identified that such application or administration of a crosslinking reagent to fibrotic tissue allows for improved stability and strength of the tissue.

The present invention relates to administration or application of a crosslink inducing agent to a subject following a stiffening procedure to the respiratory system. The present invention has identified that such application or administration of a crosslinking reagent to fibrotic tissue allows for improved stability and strength of the tissue.

Some embodiments of the invention include methods of using a compound such as Formula (I), Formula (II), or I-1 (e.g., in compositions or in pharmaceutical compositions) for treating diseases (e.g., cancer such as chemo-resistant cancer or cancer-therapy-resistant cancer). Additional embodiments of the invention are also discussed herein.